# Sales Navigator in MedTech: the missing signal (2026)

Sales Navigator identifies who exists, and its Buyer Intent reads LinkedIn activity. But it misses the public MedTech buying signals (BOAMP, ARS, HAS) that date the buying window.

URL: https://agify-md.fr/en/medify/sales-navigator-medtech-signal-achat/

In B2B sales, the first vendor to make contact wins 8 deals out of 10, and that first contact happens 61% of the way through the buying journey (6sense, 2025 B2B Buyer Experience Report, nearly 4,000 buyers surveyed). In other words, the advantage is won before the competitive bidding, at the moment the buyer tips into buying mode. The real question isn’t who to prospect, but when.

That is exactly where Sales Navigator ends and a buying signal agent begins. Sales Navigator identifies who exists and lets you reach them. It doesn’t tell you when a healthcare facility is ready to buy, or why. In MedTech, that trigger lives in public registries (a tender in BOAMP, France’s official public procurement bulletin; a certification from the HAS, France’s National Authority for Health; an authorization from an ARS, a regional health agency), never in LinkedIn activity. The two tools don’t replace each other; they stack.

This article explains what Sales Navigator really covers in 2026, Buyer Intent included, which MedTech buying signals it misses by design, and how to combine the two layers without giving up either.

## Is Sales Navigator enough for MedTech prospecting?

No. Sales Navigator identifies who exists and lets you get in touch, but it doesn’t point to the facility that is ready to buy. It’s an identity and execution layer (filters, profiles, InMail, network), not a public buying signal layer. In MedTech, the buying window opens with a tender or a compliance deadline, not with a profile view. Sales Navigator is still useful; it’s just incomplete on its own.

The reason is statistical. In any given market, about 5% of buyers are actually in buying mode at a given moment, and the other 95% aren’t (the 95-5 rule, from the LinkedIn B2B Institute with the Ehrenberg-Bass Institute, *How B2B Brands Grow*). A targeting tool gives you the full 100%. It doesn’t tell you which of the 100 just tipped into the active 5%. That tipping point, and that alone, determines a campaign’s return.

So the heart of MedTech prospecting isn’t access to names, which Sales Navigator, Apollo, and ZoomInfo already solve, but detecting the moment. In the French hospital market, [those contact databases miss public buying signals](https://agify-md.fr/en/medify/apollo-lusha-zoominfo-hopital/). Owning the names isn’t enough anyway: [a purchased healthcare contact database loses value from day one](https://agify-md.fr/en/medify/base-donnees-b2b-sante-actif-mort/), because a list freezes an identity without capturing the buying signal. That’s the whole logic of [buying-signal prospecting in the hospital market](https://agify-md.fr/en/medify/prospection-medtech-france/): you contact a facility because it is preparing a decision, not because it’s on a list.

## What does Sales Navigator’s Buyer Intent actually detect?

Sales Navigator’s Buyer Intent aggregates more than 180 behavioral signals drawn from LinkedIn activity (profile views, engagement with your company page, InMail acceptance, interactions with your content) and from visits to your own website. It’s a real intent score, but it’s built entirely on what happens inside the LinkedIn ecosystem and on your own channels. It doesn’t read any external public source.

Since late 2025, LinkedIn has expanded this feature with an AI-powered Buyer Intent filter, available only in the Advanced and Advanced Plus editions. For accounts already engaging with your brand, that’s valuable: [Sales Navigator’s Buyer Intent](https://www.linkedin.com/help/sales-navigator/answer/a798004) spots accounts that are warming up and prioritizes your follow-ups. The limit isn’t the quality of the signal; it’s the source.

That score depends on two conditions: the buyer has to be active on LinkedIn, and they have to have already crossed paths with your company (page, content, website). In MedTech, though, the decision-makers who open a buying window (heads of department, hospital IT leaders, biomedical engineers, purchasing managers) are often barely active on LinkedIn, and their buying trigger is a public administrative act, not a click. Buyer Intent can’t see a budget approved by a board of directors or a prior information notice published in BOAMP.

## Which MedTech buying signals does Sales Navigator miss?

Sales Navigator doesn’t capture any public hospital buying signal. A BOAMP tender, an ARS equipment authorization, an expiring HAS certification, a new head of department or CIO, a practitioner’s identity in the RPPS (France’s national registry of healthcare professionals): these triggers live in French public registries, never on LinkedIn. Yet they are what dates a healthcare facility’s buying window.

These signals have a property LinkedIn activity lacks: they are objective and they come before any contact. A published tender commits a budget. An expiring certification forces a compliance effort. An ARS authorization unlocks heavy equipment. None of these events leaves the slightest trace in a LinkedIn intent score.

| MedTech buying signal | Public source | What it announces |
|---|---|---|
| Tender, prior information notice | BOAMP | Formal purchase under way or planned |
| Heavy equipment authorization | ARS | Approved budget for an MRI, CT, or PET scanner |
| Expiring certification, scheduled visit | HAS | Imminent compliance work |
| Appointment (head of department, CIO, clinical research director) | Hospimedia, BODACC | Contract review, 90-day window |
| Identity, specialty, place of practice | RPPS | Verifiable targeting of the right practitioner |

That cross-referencing of public sources is what [detecting a BOAMP tender before the specifications are written](https://agify-md.fr/en/medify/appel-offres-boamp-amont/) covers in detail, and what [HAS certification scores that date a buying window](https://agify-md.fr/en/medify/certification-has-signal-achat/) illustrate. Read together for the same facility, they turn a weak hint into a dated opportunity. Each registry is reviewed in [the breakdown of the eight public sources Sales Navigator can’t see](https://agify-md.fr/en/medify/sales-navigator-marche-hospitalier/).

## Why are Sales Navigator and a buying signal agent complementary?

Because they answer two different questions. Sales Navigator answers “who exists and how do I reach them”: filters, identity, InMail, network. A signal agent answers “who is buying now, and why”: it monitors public sources and triggers contact at the right moment. Most MedTech teams use both. Without a timing signal, the right message goes out in the wrong window.

It fits in one sentence: Sales Navigator identifies who exists; a signal agent tells you when and why to reach out. The first layer is necessary but not sufficient. The second without the first would leave a signal with no one to talk to. Together, they connect a public buying event to a reachable person.

It all comes back to first contact. Since the first vendor to make contact wins 8 times out of 10, and that contact happens earlier and earlier in the journey, getting there before the bidding isn’t a nice-to-have; it’s the decisive edge. The public signal is what gets you there early. Sales Navigator is what gets you to the right person. That’s the core principle of [reverse prospecting, which detects the need before pushing the message](https://agify-md.fr/en/leadify/prospection-inversee-signaux-achat/).

## How do you combine Sales Navigator with buying signal monitoring?

Keep Sales Navigator for identity and execution (finding the right contact, sending the InMail, nurturing the network) and add a layer that monitors public sources for prioritization. The public signal points to the facility that’s ready to buy; Sales Navigator then helps you reach the right person inside that facility. The FINESS code (from France’s national registry of healthcare facilities) links the two layers on the same account.

In practice, signal monitoring runs continuously on public registries, spots a trigger (a tender, a certification, an appointment), identifies the facility and its decision-maker, and pushes the file to the top of the list. Sales Navigator takes over for execution: exact profile, channel, message. One without the other leaves you with either an orphaned signal or a contact with no timing.

That’s exactly the framing we set up in a [MedTech prospecting scoping call](https://cal.com/team/agify/audit-prospection-medtech?utm_source=agify-md.fr&utm_medium=site&utm_campaign=article-medify&utm_content=appel-section): translating a product catalog into public signals to monitor, and plugging that detection into the execution tools already in place. It’s also Agify’s engine, which automates this monitoring across public healthcare sources. For a French MedTech company specializing in medical imaging, cross-referencing more than ten public sources made it possible, in six weeks, to keep only the truly qualified European radiologists, as detailed in [this case study on prospecting radiologists through buying signals](https://agify-md.fr/en/medify/prospection-radiologues-imagerie/). Once the target is identified on LinkedIn, the right message at the right time makes the difference: [a LinkedIn campaign aimed at senior physicians](https://agify-md.fr/en/medify/prospection-linkedin-medecins/) achieved nearly double the healthcare industry’s average reply rate.

## Frequently asked questions

### Should you drop Sales Navigator if you adopt a buying signal agent?

No. The two layers complement each other. Sales Navigator remains the identity and execution tool: it finds the right person and lets you reach them. A signal agent adds the timing dimension that Sales Navigator doesn’t provide for the French hospital market. Most MedTech teams keep Sales Navigator and plug public source monitoring into it.

### Does Sales Navigator’s Buyer Intent cover French hospitals?

Partially, and indirectly. Buyer Intent measures LinkedIn activity and visits to your website. But hospital decision-makers (heads of department, IT leaders, buyers) are often barely active on LinkedIn, and their buying trigger is a public act (a tender, an authorization, a certification) that leaves no trace in that score. In this market, Buyer Intent is a supplement, not a reliable source of timing.

### Which Sales Navigator edition gives you access to Buyer Intent?

Buyer Intent and its AI-powered filter are reserved for the Sales Navigator Advanced and Advanced Plus editions. The Core edition doesn’t include it. Whatever the edition, the feature stays focused on LinkedIn activity and visits to your own website.

### How long does a buying signal stay usable?

Not long. A buying signal goes stale quickly: after a few weeks, the buyer has often already built their vendor shortlist. Since the first vendor to make contact wins 8 times out of 10, and 95% of buyers purchase from one of the four vendors on their day-one list, a signal’s value depends on how fast you react.

### Does Radar replace Sales Navigator?

No. Radar adds the layer Sales Navigator lacks: monitoring public MedTech buying signals and triggering contact at the right moment. It works alongside existing identity and execution tools rather than replacing them. The distinction is clear: Sales Navigator gives you the who; Radar gives you the when and the why.

## Conclusion

“We already have Sales Navigator” and “we need a signal agent” aren’t contradictory. Three takeaways: Sales Navigator excels at identity and execution, and its Buyer Intent reads LinkedIn activity but stays blind to public registries; MedTech buying signals (BOAMP, ARS, HAS, RPPS) date the buying window and never go through LinkedIn; and since first contact often decides the deal, it’s the public signal that gets you there in time.

What’s left is figuring out which signals matter in your specific market. Let’s talk through your case in 30 minutes: together we’ll identify the public sources that announce your opportunities, and how to plug them into the tools your sales reps already use.

---

*Agify deploys autonomous AI prospecting agents inside B2B sales teams, with a specialization in the French MedTech market and its public healthcare and procurement sources.*